Literature DB >> 795498

Combined dexamethasone and low-molecular-weight dextran in acute brain infarction: double-blind study.

M Kaste, R Fogelholm, O Waltimo.   

Abstract

Intramuscular dexamethasone combined with intravenous low-molecular-weight dextran (dextran 40) was compared with placebo in 40 patients with acute ischaemic cerebral infarction. A double-blind procedure was used. Dexamethasone was given for up to 14 days and dextran 40 for up to three days after the infarction. A weighted scoring system was used to evaluate neurological state and mobility. There were no differences in mortality or in improvement of the neurological or mobility scores between the two groups.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 795498      PMCID: PMC1690349          DOI: 10.1136/bmj.2.6049.1409

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  7 in total

1.  Dexamethasone as treatment in cerebrovascular disease. 2. A controlled study in acute cerebral infarction.

Authors:  R B Bauer; H Tellez
Journal:  Stroke       Date:  1973 Jul-Aug       Impact factor: 7.914

2.  Effect of low molecular dextran on total cerebral blood flow and on regional flow within ischemic brain lesions.

Authors:  W D Heiss; P Prosenz; H Tschabitscher; C Lasek; H J Herles
Journal:  Eur Neurol       Date:  1972       Impact factor: 1.710

3.  Double-blind study of the effects of dexamethasone on acute stroke.

Authors:  B M Patten; J Mendell; B Bruun; W Curtin; S Carter
Journal:  Neurology       Date:  1972-04       Impact factor: 9.910

4.  Management of completed strokes with dextran 40. A community hospital failure.

Authors:  E V Spudis; E De la Torre; L Pikula
Journal:  Stroke       Date:  1973 Nov-Dec       Impact factor: 7.914

5.  Treatment of acute stroke with dextran 40.

Authors:  J Gilroy; M I Barnhart; J S Meyer
Journal:  JAMA       Date:  1969-10-13       Impact factor: 56.272

6.  Steroid therapy in acute cerebral infarction.

Authors:  J W Norris
Journal:  Arch Neurol       Date:  1976-01

7.  A blind controlled trial of dextran 40 in the treatment of ischaemic stroke.

Authors:  W B Matthews; J M Oxbury; K M Grainger; R C Greenhall
Journal:  Brain       Date:  1976-06       Impact factor: 13.501

  7 in total
  10 in total

1.  Effect of hypervolaemic haemodilution of regional cerebral blood flow in patients with acute ischaemic stroke: a controlled study with hydroxyethylstarch.

Authors:  A Hartmann; Y Tsuda; H Lagrèze
Journal:  J Neurol       Date:  1987-10       Impact factor: 4.849

Review 2.  Clinical trials in acute ischemic stroke.

Authors:  Kiyoshi Kikuchi; Eiichiro Tanaka; Yoshinaka Murai; Salunya Tancharoen
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

Review 3.  Drug treatment of stroke. Current status and future prospects.

Authors:  C A Sila; A J Furlan
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

4.  Complete cerebral recovery after prolonged circulatory arrest. A report of two cases.

Authors:  A Gilston
Journal:  Intensive Care Med       Date:  1979-11       Impact factor: 17.440

Review 5.  Pharmacological treatment for aphasia following stroke.

Authors:  J Greener; P Enderby; R Whurr
Journal:  Cochrane Database Syst Rev       Date:  2001

6.  Treatment of acute cerebral infarction.

Authors: 
Journal:  Br Med J       Date:  1977-01-01

Review 7.  Corticosteroids for acute ischaemic stroke.

Authors:  Peter Ag Sandercock; Tim Soane
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 8.  A review of red cell transfusion in the neurological intensive care unit.

Authors:  Shanthan Pendem; Sameer Rana; Edward M Manno; Ognjen Gajic
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 9.  Therapeutic interventions in acute stroke.

Authors:  K R Lees
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

Review 10.  Haemodilution for acute ischaemic stroke.

Authors:  Timothy S Chang; Matthew B Jensen
Journal:  Cochrane Database Syst Rev       Date:  2014-08-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.